The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy - Concepedia

Concepedia

Publication | Closed Access

The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy

12

Citations

20

References

2013

Year

T. Rhodes, Josephine M. Norquist, Christine McCrary Sisk, Kelly McQuarrie, A Trovato, Jifeng Liao, Todd D. Miller, Darbie Maccubbin, D.J. Watson

International Journal of Clinical Practice

Abstract

In a real-world setting, NIF side effects were bothersome and had an impact on the continuation of therapy.

References

	Year	Citations
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Circulation Health PolicyCardiovascular DiseaseExpert PanelHigh Blood CholesterolHyperlipidemia	2002	13.9K
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Scott M. Grundy, Diane M. Becker, Luther T. Clark, Civil War Book Review Cardiovascular DiseaseHigh Blood CholesterolHyperlipidemiaDyslipidemiaPublic Health	2002	12.2K
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy New England Journal of Medicine	2011	2.9K
Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. William P. Castelli, Robert J. Garrison, Peter W.F. Wilson, PubMed HypertensionHyperlipidemiaCoronary Artery DiseaseBody CompositionClinical Epidemiology	1986	2.3K
Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease Bryan Brown, Xue-Qiao Zhao, Alan Chait, New England Journal of Medicine	2001	2K
Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin Paul L. Canner, Kenneth G. Berge, Nanette K. Wenger, Journal of the American College of Cardiology Cardiovascular DiseaseHealth PolicyLong-term BenefitCardiovascular PharmacologyFifteen Year Mortality	1986	1.8K
Clofibrate and Niacin in Coronary Heart Disease JAMA	1975	1.7K
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels William P. Castelli JAMA HypertensionCardiometabolic RiskHyperlipidemiaPreventive CardiologyCoronary Artery Disease	1986	1.6K
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Mark J. Atkinson, Anusha Sinha, Steven Hass, Health and Quality of Life Outcomes	2004	939
Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin Robert H. Knopp, Janice Ginsberg, John J. Albers, Metabolism Lipid DisorderHyperlipidemic SubjectsBiochemistryTime-release FormsMedicine	1985	233

Page 1